The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study
Condition(s):Breast CancerLast Updated:February 12, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Breast CancerLast Updated:February 12, 2024Recruiting
Condition(s):Breast CancerLast Updated:February 7, 2024Not yet recruiting
Condition(s):Breast Cancer; Estrogen Receptor Positive Tumor; HER2-positive Breast CancerLast Updated:February 21, 2023Recruiting
Condition(s):Breast Cancer; Brain Metastases; HER2-positive Breast CancerLast Updated:January 18, 2023Active, not recruiting
Condition(s):HER2-positive Recurrent/Metastatic Breast CancerLast Updated:November 18, 2022Not yet recruiting
Condition(s):Breast Cancer Stage ILast Updated:March 22, 2024Recruiting
Condition(s):HER2-positive Advanced Breast CancerLast Updated:May 12, 2023Recruiting
Condition(s):Healthy Subjects, Drug-drug Interaction, PyrotinibLast Updated:April 22, 2021Unknown status
Condition(s):Healthy ParticipantsLast Updated:October 28, 2022Completed
Condition(s):Breast CancerLast Updated:May 30, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.